One gap in our understanding of the biology of HPV infection is that it is not known if infection with an HPV type confers immunity to subsequent reinfection with the same type. The availability of sensitive and specific serological assays using virus-like particles (VLPs) composed of HPV capsid proteins now makes it possible to address this issue. Studies to determine whether anti-capsid protein antibodies will prevent infection in human populations would have relevance for efforts to develop VLP-based vaccines and may provide an estimate of the level of anti-capsid antibody that a vaccine would have to induce in order to be protective. We recently obtained permission to test serum specimens from women enrolled in three large prospective studies of the natural history of HPV infection; the CDC sponsored HERS, the NIH sponsored WIHS, and the NCI sponsored Guanacaste Project in Costa Rica. The former two studies include HIV positive and HIV negative women. Because HIV infected individuals may be a prime target population for an HPV vaccine, it is important to know if the relationship of pre-existing anti-HPV antibodies to the risk of subsequent HPV infection for these women is the same or different from that for HIV negative women. Recruitment sera from women enrolled in three studies will be tested by ELISA for antibodies to VLPs of HPV-16, -31, -18, -45, -6, and -11. The antibody status at recruitment will be related to incident HPV infection and/or disease over a follow-up period of 4-7 years. The following are the questions to be addressed in this proposal: (1) Are serum antibodies to VLPs of a particular HPV type associated with a decreased frequency of incident infection with that HPV type? (2) Are serum antibodies to an HPV type associated with a decreased frequency of incident infection with genetically closely related types? (3) What is the minimum level of VLP antibodies that confers full protection? (4) Are serum antibodies to VLPs associated with reinfections characterized by a lower viral load, shorter duration of viral shedding and/or lower risk of cytological abnormalities than that of incident infections in antibody negative women? (5) Are serum antibodies to HPV VLPs in HIV seropositive women, as compared to HIV seronegative women, associated with the same or a higher frequency of incident HPV infection and/or disease? (6) In HIV seropositive women, is the extent of immunodeficiency, as measured by CD4+ cell counts, inversely correlated with the degree of protection provided by pre-existing anti-VLP antibodies?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI042058-04
Application #
6373722
Study Section
Special Emphasis Panel (ZRG4-EDC-2 (01))
Program Officer
Savarese, Barbara M
Project Start
1998-08-01
Project End
2003-07-31
Budget Start
2001-08-01
Budget End
2003-07-31
Support Year
4
Fiscal Year
2001
Total Cost
$327,904
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Silverberg, Michael J; Schneider, Michael F; Silver, Barbara et al. (2006) Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol 13:511-9
Viscidi, Raphael P; Snyder, Brad; Cu-Uvin, Susan et al. (2005) Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14:283-8
Kreimer, Aimee R; Alberg, Anthony J; Viscidi, Rapheal et al. (2004) Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 31:247-56
Viscidi, Raphael P; Ahdieh-Grant, Linda; Schneider, Michael F et al. (2003) Serum immunoglobulin A response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 188:1834-44
Viscidi, Raphael P; Ahdieh-Grant, Linda; Clayman, Barbara et al. (2003) Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 187:194-205
de Sanjose, Silvia; Shah, Keerti V; Domingo-Domenech, Eva et al. (2003) Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer 104:522-4
Viscidi, Raphael P; Rollison, Dana E M; Viscidi, Emma et al. (2003) Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10:278-85
Nakagawa, Mayumi; Viscidi, Raphael; Deshmukh, Ian et al. (2002) Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol 9:877-82
Sun, Y; Eluf-Neto, J; Bosch, F X et al. (1999) Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol Biomarkers Prev 8:935-40